Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Secondary (aka ischaemic or Carpentier surgical classification Type IIIb) mitral regurgitation (MR) is a common complication of coronary artery disease and is associated with adverse prognosis.1 The fundamental mechanism of ischaemic MR relates to remodelling and distortion of the ischaemic left ventricle (LV). As viable myocardial cells are lost following infarction, the wall becomes thinner and bulges outward, a process that begins almost immediately and then progresses over weeks to months. As a result of ischaemic LV distortion and dilation, the mitral leaflets become tethered towards the apex, restricting leaflet closure.2 Standard mitral valve repair for ischaemic MR at the time of revascularisation involves placing an undersized rigid mitral valve (MV) annuloplasty ring (restrictive mitral annuloplasty, RMA) to restore coaptation by correcting posterior annular dilatation. However, RMA does not eliminate the mechanistic problem in ischaemic MR, which is a subvalvular problem with altered geometry of the chordal apparatus due to ventricular dilation from coronary artery disease or cardiomyopathy.
In their paper in Heart, Harmel and colleagues3 performed a meta-analysis of 1 prospective and 11 retrospective trials examining outcomes of the addition of one of several subannular procedures in addition to RMA for ischaemic MR and conclude that the addition of such procedure(s) is associated with a substantially lower rate of recurrent MR.
Harmel and colleagues3 highlight an important unmet need in MV therapy, which is a need for a …
Contributors All authors contributed to initial draft and final editing of this article.
Funding This study was funded by the National Institute of Health/NHLBI.
Competing interests JH is on SAB of Chordalign. JSG is consultant for Edwards Lifesciences. GA is consultant for Abbott, Edwards Lifesciences, Medtronic and Cephea.
Patient consent Not required.
Provenance and peer review Commissioned; internally peer reviewed.